CHAPEL HILL, N.C., Jan. 30 /PRNewswire/ -- New research has shown that companies can take advantage of opportunities and manage risk by collecting and understanding intelligence through the competitive or business intelligence function. In an effort to better understand the best practices in developing effective and legally sound data collection procedures, a recent study was conducted by Best Practices, LLC, with insights available in the newly published report, "Competitive Intelligence Policies, Ethics, and Data Collection: Navigating the Gray Zone." This benchmarking study was conducted to understand how U.S. pharmaceutical and biotechnology organizations can optimize their CI/BI operations while working within defined guidelines.
The research examined a number of topics, including:
The performance metrics found in this study were gathered from industry experts including those from such top companies as Amgen, Baxter, Eli Lilly, Merck, Roche and Wyeth.
Key findings from the study include:
For more information on this report, contact Robert Naylor at firstname.lastname@example.org or (919) 767-9244. To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/rr976.htm.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.
|SOURCE Best Practices, LLC|
Copyright©2009 PR Newswire.
All rights reserved